Etanercept in New Onset Type 1 Diabetes

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

October 31, 2002

Primary Completion Date

October 31, 2007

Study Completion Date

January 31, 2008

Conditions
Type 1 Diabetes
Interventions
DRUG

Etanercept

The study drug was provided in lyophilized 10 mg vials to be reconstituted with 1 ml of diluent/vial and was administered at a dose of 0.4 mg/Kg up to maximum dose of 25 mg/dose SC twice weekly

DRUG

Placebo

administered at 0.4 mg/Kg/dose SC up to 25 mg max twice weekly

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Amgen

INDUSTRY

lead

State University of New York at Buffalo

OTHER